Pharma Industry Reputation Improves Among Patient Groups, Yet Access and Pricing Concerns Persist

The pharmaceutical industry’s reputation among patient groups saw a modest improvement in 2025, according to a new survey by PatientView. However, this positive shift is overshadowed by persistent concerns regarding access to medicines and pricing.

The survey, which included responses from over 2,400 patient groups across 35 countries between December 2025 and March 2026, found that 57% of groups rated drugmakers’ reputation as “excellent” or “good” in 2025. This marks a slight increase from 56% in 2024 and aligns with the 2023 level. Despite the uptick, the industry still falls short of the 60% rating achieved in 2022.

Key Drivers of Reputation Improvement

Patient centricity and patient safety were identified as the primary factors contributing to the industry’s improved reputation. These elements reflect a growing emphasis among pharmaceutical companies on addressing patient needs and ensuring treatment safety.

Industry Performance by the Numbers

• 2025 reputation rating: 57% (excellent or good)
• 2024 reputation rating: 56%
• 2023 reputation rating: 57%
• 2022 reputation rating: 60%
• Number of patient groups surveyed: Over 2,400
• Countries represented: 35
• Companies evaluated: 47

Ongoing Challenges

Despite the incremental progress, the survey highlights that patient groups continue to harbor concerns about access to medicines and pricing. These issues remain critical barriers to the industry’s ability to fully meet patient needs.

PatientView’s findings underscore the need for pharmaceutical companies to not only maintain their focus on patient safety and centricity but also address systemic challenges in affordability and accessibility to sustain long-term trust and reputation.